Insmed (INSM) Net Income towards Common Stockholders (2010 - 2026)

Insmed's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$163.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 36.25% year-over-year to -$163.6 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 16.83% YoY), while the FY2025 annual figure was -$1.3 billion, down 39.73% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$163.6 million, up from -$328.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$94.6 million in Q1 2022, with the low at -$370.0 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$186.1 million (2023), against an average of -$210.9 million.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders plunged 155.96% in 2023, then soared 36.25% in 2026.
• Insmed's Net Income towards Common Stockholders stood at -$160.1 million in 2022, then fell by 16.2% to -$186.1 million in 2023, then retreated by 26.6% to -$235.5 million in 2024, then plunged by 39.46% to -$328.5 million in 2025, then jumped by 50.21% to -$163.6 million in 2026.
• Business Quant data shows INSM's Net Income towards Common Stockholders at -$163.6 million in Q1 2026, -$328.5 million in Q4 2025, and -$370.0 million in Q3 2025.